Full Press Release Details
("Midatech" or the "Company")
Posting of Annual Report & Notice
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, announces that its Notice
of Annual General Meeting ("AGM") was posted to shareholders, along with the Annual Report and Financial Statements for
the year ended 31 December 2018, on 24 May 2019. The document is available today on the "Investors" section of the Company's
The Company will be holding its AGM at
the offices of Panmure Gordon & Co, One New Change, London EC4M 9AF on Wednesday 19 June 2019 at 11:00 a.m.
For more information, please contact:
(UK) Limited (Nominated Adviser and Broker)
Emma Earl (Corporate Finance)
Limited (Financial PR and UK Investor Relations)
/ Tim Metcalfe / Heather Armstrong
Westwicke Partners (US Investor Relations)
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Pharma (LSE AIM: MTPH; NASDAQ: MTP) is an R&D company focused on delivering innovative oncology and rare disease products to
patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary
platform drug delivery technologies, all of which are in the clinic, specifically:
of our three technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the
body where they are needed and can exert their actions in an effective, safe and precise manner.
headquarters and R&D facility is in Cardiff, UK, with a manufacturing operation in Bilbao, Spain. For more information please
visit www.midatechpharma.com